Department of Medical Parasitology, Faculty of Medicine, Tanta University, Tanta, Egypt.
Department of Pathology, Faculty of Medicine, Tanta University, Tanta, Egypt.
Exp Parasitol. 2024 Jul;262:108775. doi: 10.1016/j.exppara.2024.108775. Epub 2024 May 11.
The limited activity of the traditional medications against T. spiralis encysted larvae handicaps complete cure of trichinellosis till now due to decreased permeability and absorption through tissues. MOX is listed worldwide for prevention and treatment of several internal and external nematodes. Consequently, the aim of this work was to investigate the effect of moxidectin versus ivermectin on experimental acute and chronic trichinellosis and to illuminate the potential mechanisms of their effects. 105 Mice were divided into four groups; Group I: Uninfected healthy control; Group II: Infected untreated control; Group III: Infected and treated with IVM and Group IV: Infected and treated with MOX. The groups (II, III and IV) were later subdivided equally into three subgroups (a, b, and c) according to the stage of treatment. Parasitological counting of adults and larvae besides immune-histopathological examination of intestines and muscles were done. Results exhibited that both IVM and MOX succeeded in reducing adults and larvae counts with higher potential of MOX in both intestinal and muscle phase. The preeminence of MOX was indicated by decreased inflammation, a significant reduction in the microvascular density (CD31 immunostaining) as well as a reduction in the percentage of fibroblast activation protein (FAP) immunostaining in muscle tissues. Accordingly, the current work recommends moxidectin as an innovative treatment for trichinellosis.
由于组织通透性和吸收降低，传统药物对旋毛虫囊包幼虫的有限活性阻碍了目前对旋毛虫病的完全治愈。莫昔克丁已在全球范围内被列为预防和治疗多种内部和外部线虫的药物。因此，本研究旨在探讨莫昔克丁与伊维菌素对实验性急性和慢性旋毛虫病的影响，并阐明其作用的潜在机制。将 105 只小鼠分为四组；第 I 组：未感染的健康对照组；第 II 组：未感染的未治疗对照组；第 III 组：感染并接受 IVM 治疗组；第 IV 组：感染并接受 MOX 治疗组。根据治疗阶段，后两组（III 和 IV 组）又均等分为三个亚组（a、b 和 c）。对成虫和幼虫进行寄生虫计数，对肠道和肌肉进行免疫组织病理学检查。结果表明，IVM 和 MOX 均能成功降低成虫和幼虫的数量，MOX 在肠道和肌肉阶段的效果更强。MOX 的优势在于炎症减少，微血管密度（CD31 免疫染色）显著降低，以及肌肉组织中成纤维细胞激活蛋白（FAP）免疫染色的百分比降低。因此，本研究推荐莫昔克丁作为一种治疗旋毛虫病的创新方法。
